Abstract 1749
Background
Tumor genomic profiling is a critical component of precision oncology allowing the detection of genomic alterations (GA) that can be therapeutically targeted. We present an analysis of the results of comprehensive genomic profiling (CGP) from a large series of patients assayed in the setting of a community practice cancer network.
Methods
IRB-approved analysis of pts assayed with CGP using hybrid-capture NGS based CGP assays were performed on 6,177 pts with advanced cancer during the course of clinical care for the purpose of making therapy decisions, with GA suggesting the latter labeled as clinical relevant. Three genomic platforms were utilized, FoundationOne (315 genes, 89% of tests), FoundationOne-Heme (405 genes, 6%) and FoundationAct, (62 genes, 5%)
Results
From 01-2013 to 09-2017, clinical samples from 6,177 pts (6496 CGP assays) with advanced cancer underwent CGP. Median age was 56 years (range, 18-94), 61% of pts were female, 68% were Caucasian. The most common tumor types studies were breast (18%), colorectal (15%), lung (14%), gynecological (11%) and unknown cancer (10%). GA were identified in 94% (5839/6496) of cases, and GA were classified as clinically relevant (47%)/not clinical relevant (52.6%). The most frequent clinically relevant GA were in KRAS(23%) and PIK3CA(15%). The most common genomic alterations were amplification (32%). Treatment history for a large subset of patients (4490) showed that 23% (1169/4490) of pts were ordered a genomically-matched treatment, 57% (662/1169) of which were tied to an FDA approved agent in a different tumor type, and 15% of which (178/1169) were referred to a matched mechanism driven clinical trial. With the access to TAPUR the frequency of matched treatment for clinical trials increased over time from 2013 to 2017.
Conclusions
In a large series of diverse patients assayed with CGP in the community setting, 23% of patients received matched treatment, which was predominantly targeted therapy. The increasing frequency of matching treatment over time and the advent of immunotherapy and matching with PDL1 and tumor mutational burden may further increase the proportion of this population . Future analysis will explore outcomes for this subset of pts.
Clinical trial identification
Editorial Acknowledgement
Resources from the same session
4814 - Molecular characterization of epithelioid sarcoma (ES) tumors derived from patients enrolled in a phase 2 study of tazemetostat (NCT02601950)
Presenter: Mrinal Gounder
Session: Proffered paper session - Basic science
Resources:
Abstract
Slides
6258 - Defining the lethal subclone in metastatic lung cancer
Presenter: Mariam Jamal-Hanjani
Session: Proffered paper session - Basic science
Resources:
Abstract
Proffered paper session - Basic science - Invited Discussant 1891O, 1892O and LBA11
Presenter: Samra Turajlic
Session: Proffered paper session - Basic science
Resources:
Slides
Webcast
3542 - KRAS mutant and RAS/BRAF wild type colorectal cancer cells exhibit differences in the rewiring of signal transduction that can impact on future therapeutic strategies
Presenter: Alexandros Georgiou
Session: Proffered paper session - Basic science
Resources:
Abstract
Slides
Webcast
4599 - Receptor Tyrosine Kinase dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated colorectal cancer cell lines.
Presenter: Pietro Paolo Vitiello
Session: Proffered paper session - Basic science
Resources:
Abstract
Slides
Webcast
Proffered paper session - Basic science - Invited Discussant 1O and 2O
Presenter: Alberto Bardelli
Session: Proffered paper session - Basic science